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Research
Heart rate variability (HRV) is a noninvasive
measure reflecting autonomic cardiac function
that independently predicts death and
arrhythmic complications in apparently
healthy middle-age and elderly subjects (Task
Force of the European Society of Cardiology
and the North American Society of Pacing and
Electrophysiology 1996; Tsuji et al. 1994,
1996). Disturbances in autonomous nervous
system function reflected by decreased HRV
may represent one pathway by which tobacco
smoke, including second-hand smoke (SHS),
and air pollutants trigger cardiovascular
mortality and morbidity (Pope et al. 2001,
2004). The specific mechanisms by which these
inhalants affect neural control of the heart are
the focus of ongoing research. One potentially
important pathway is oxidative stress (Brook
et al. 2003; Cascio 2005; Nel 2005), because
inhaled smoke (and other pollutants) provokes
oxidative stress and an inflammatory response
in the lung and heart (Donaldson et al. 2005;
Gurgueira et al. 2002; Zhang et al. 2001,
2002). Although reactive oxygen species (ROS)
have an established importance in the patho-
genesis of cardiovascular diseases (Dhalla et al.
2000), their specific impact on autonomous
nervous system activity and its reaction to
inhalants remains to be established. Recent
studies provide evidence for oxidative stress as
one of the mechanisms for the effect of air pol-
lution on HRV (Cascio 2005). We have
demonstrated that the acute effect of particulate
matter (PM) air pollution on HRV is modified
by polymorphisms in the glutathione S-trans-
ferase (GST) gene GSTM1 (Schwartz et al.
2005) and the hemochromatosis gene HFE
(Park et al. 2006), both exhibiting antioxidative
properties (Forsberg et al. 2001; Hayes and
Strange 2000; Park et al. 2006). Common
polymorphisms in GST genes were previously
found to modify respiratory effects of inhaled
toxicants in children, asthmatics, smokers, and
the general population (Gilliland et al. 2002;
He et al. 2002; Kabesch et al. 2004; Romieu
et al. 2004) and to interact with tobacco smoke
to increase the risk of coronary heart disease
(Tamer et al. 2004). Romieu et al. (2005)
demonstrated that dietary supplementation
with plant-derived n-3 polyunsaturated fatty
acids, known for their antioxidative properties,
abrogated the acute association between fine
PM and decreased HRV in a cohort of elderly
Mexicans. However, these studies have dealt
with only acute exposure scenarios and short-
term changes in HRV, whereas most studies
have linked baseline HRV to cardiovascular risk
(Task Force of the European Society of
Cardiology and the North American Society of
Pacing and Electrophysiology 1996; Tsuji et al.
1994, 1996).
To further investigate the hypothesis of an
ROS impact on autonomous nervous system
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BACKGROUND: Disturbances of heart rate variability (HRV) may represent one pathway by which
second-hand smoke (SHS) and air pollutants affect cardiovascular morbidity and mortality. The
mechanisms are poorly understood.
OBJECTIVES: We investigated the hypothesis that oxidative stress alters cardiac autonomic control.
We studied the association of polymorphisms in oxidant-scavenging glutathione S-transferase
(GST) genes and their interactions with SHS and obesity with HRV.
METHODS: A total of 1,133 nonsmokers > 50 years of age from a population-based Swiss cohort
underwent ambulatory 24-hr electrocardiogram monitoring and reported on lifestyle and medical
history. We genotyped GSTM1 and GSTT1 gene deletions and a GSTP1 (Ile105Val) single
nucleotide polymorphism and analyzed genotype–HRV associations by multiple linear regressions.
RESULTS: Homozygous GSTT1 null genotypes exhibited an average 10% decrease in total power (TP)
and low-frequency-domain HRV parameters. All three polymorphisms modified the cross-sectional
associations of HRV with SHS and obesity. Homozygous GSTM1 null genotypes with > 2 hr/day of
SHS exposure exhibited a 26% lower TP [95% confidence interval (CI), 11 to 39%], versus a reduc-
tion of –5% (95% CI, –22 to 17%) in subjects with the gene and the same SHS exposure compared
with GSTM1 carriers without SHS exposure. Similarly, obese GSTM1 null genotypes had, on aver-
age, a 22% (95% CI, 12 to 31%) lower TP, whereas with the gene present obesity was associated
with only a 3% decline (95% CI, –15% to 10%) compared with nonobese GSTM1 carriers.
CONCLUSIONS: GST deficiency is associated with significant HRV alterations in the general popula-
tion. Its interaction with SHS and obesity in reducing HRV is consistent with an impact of oxida-
tive stress on the autonomous nervous system.
KEY WORDS: cohort, glutathione S-transferase, heart rate variability, obesity, oxidative stress, poly-
morphism, SAPALDIA, second-hand smoke. Environ Health Perspect 116:1494–1499 (2008).
doi:10.1289/ehp.11402 available via http://dx.doi.org/ [Online 18 July 2008]
activity in the general population, we have
investigated the association between polymor-
phisms in GSTM1, GSTT1, and GSTP1 and
changes in HRV in male and female partici-
pants in the population-based SAPALDIA
cohort (Swiss Cohort on Air Pollution and
Lung and Heart Disease in Adults) ≥ 50 years
of age. To indirectly test whether the effects of
SHS were mediated by oxidative stress, we
also assessed the interaction of SHS with GST
polymorphisms and obesity.
Materials and Methods
Study population. SAPALDIA was designed to
measure the health effects of air pollutants and
has been previously described (Ackermann-
Liebrich et al. 2005; Downs et al. 2007; Martin
et al. 1997). Briefly, random samples of the
Swiss population were recruited from eight areas
featuring distinct geographic and environmental
conditions. Participants were examined in 1991
and in 2001–2003. A random sample of follow-
up participants ≥ 50 years of age participated in
a 24-hr electrocardiogram recording (n = 1,837)
(Felber Dietrich et al. 2006, 2007), including
1,133 nonsmoking subjects [see Supplemental
Material (http://www.ehponline.org/mem-
bers/2008/11402/suppl.pdf) for exclusion crite-
ria]. The study protocol complied with all
applicable ethical regulations. Participants gave
written informed consent before the study. The
study was approved by the Ethical Committee
of the Swiss Academy of Medical Sciences and
the eight cantonal ethical committees.
Interview, body mass index, and blood
pressure. SHS exposure was assessed at the in-
person interview by asking subjects how many
hours per day they were exposed to other peo-
ple’s tobacco smoke (a) at home, (b) at the
workplace, (c) in bars and restaurants, or
(d) elsewhere. We focused on SHS exposure at
home and work because these two sources
dominate overall exposure in most subjects.
We classified subjects as not exposed, exposed
≤ 2 hr/day, or exposed > 2 hr/day (Felber
Dietrich et al. 2007). Weight, height, and
body mass index (BMI; kg/m2) were based on
measuring participants without them wearing
any shoes or coats. Blood pressure was meas-
ured at rest in the sitting position on the left
upper arm by an automatic device (705CP;
OMRON, Steinhausen, Switzerland).
HRV parameters. For 24-hr electrocardio-
gram (Holter) recording, digital devices (Aria,
Del Mar Medical Systems, Irvine, CA, USA)
with a frequency response of 0.05–40 Hz and a
resolution of 128 samples/sec were used (Felber
Dietrich et al. 2006, 2007). The recorders were
hooked up after the interview. Participants were
asked to follow their regular daily life and to fill
in a time–activity diary during recording time.
Mean duration of the recordings was 22.3 ± 2.1
hr. All recordings were scanned through a
StrataScan 563 (Del Mar). Mean heart rate per
minute was derived from Holter measurements.
Spectral analysis was performed by the fast
Fourier transform method. Here we focus on
the frequency-domain variables because they
allow resolution of total HRV [total power
(TP); ≤ 0.40 Hz] into a component primarily
reflecting parasympathetic stimulation [high-
frequency (HF) power; 0.15–0.40 Hz] and a
component reflecting both sympathetic and
parasympathetic influences [low-frequency (LF)
power; 0.04–0.15 Hz] [for methodological
details, see Supplemental Material (online at
http://www.ehponline.org/members/2008/
11402/suppl.pdf); for results on time-domain
parameters SDNN (standard deviation of all
normal-to-normal intervals), SDANN (devia-
tions of the normal-to-normal R-R period), and
rMSSD (square root of the mean squared dif-
ferences of successive R-R intervals), see
Supplemental Material, Tables 1 and 2].
Blood markers and genotype. All subjects
were genotyped for GSTM1 (UniGene ID
Hs.301961; UniGene 2008a) and GSTT1
(UniGene Hs.268573; UniGene 2008b) gene
deletions and a single nucleotide poly-
morphism (SNP) in GSTP1 (UniGene
Hs.523836; UniGene 2008c) leading to the
amino acid substitution Ile105Val, as previ-
ously described (Imboden et al. 2007) [for
details, see Supplemental Material (online at
http://www.ehponline.org/members/2008/
11402/suppl.pdf)].
Statistical analysis. We assessed the asso-
ciation of log-transformed HRV with GST
genotypes, obesity, and SHS exposure by
multiple regression analyses adjusting for
study area, age (and its square), sex, diabetes,
beta-blocker intake, and fruit intake. We pre-
sent results as percent change in HRV para-
meters compared with the respective reference
groups. To assess the interactions between
SHS, GST genotypes, and obesity, we calcu-
lated trend tests by entering cross-categorized
variables into the respective regression mod-
els. We coded the cross-categorized variables
as 1 if both at-risk characteristics were absent,
2 if only one at-risk characteristic was present,
and 4 if both at-risk characteristics were pre-
sent in a subject. We performed statistical
analysis using the software package SAS ver-
sion 8.2 (SAS Institute, Inc., Cary, NC, USA)
[for details, see Supplemental Material
(http://www.ehponline.org/members/2008/
11402/suppl.pdf)].
Results
Table 1 presents characteristics of the study
population, which have also been reported in
GST polymorphisms and heart rate variability
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Table 1. Characteristics of the study population: the SAPALDIA cohort study.
Characteristic Value
Total [no. (%)] 1,133 (100.0)
Female sex [no. (%)] 594 (52.4)
Age [years (mean ± SD)] 60.6 ± 6.3
BMI [kg/m2 (mean ± SD)] 26.6 ± 4.2
≥ 30 kg/m2 [no. (%)] 223 (19.7)
SHS exposure [no. (%)]
None 956 (84.5)
≤ 2 hr/day 99 (8.7)
> 2 hr/day 78 (6.9)
Diabetes [no. (%)] 41 (3.6)
Medication [no. (%)]
Beta-blocker 135 (11.9)
ACE inhibitor 70 (6.2)
Antiarrhythmics, classes I + III 5 (0.4)
Calcium-channel blocker 53 (4.7)
Diuretics 42 (3.7)
Sympathomimetics 37 (3.3)
Uric acid [μmol/L (mean ± SD)] 323.6 ± 81.6
High-sensitivity C-reactive protein [mg/L (mean ± SD)] 2.5 ± 5.8
Non-HDL cholesterol [mmol/L (mean ± SD)] 4.7 ± 1.1
Blood pressure [mmHg (mean ± SD)]
Systolic 132.5 ± 19.3
Diastolic 81.9 ± 10.6
Heart rate [bpm (mean ± SD)] 73.5 ± 9.0
HRV (mean ± SD)
TP (msec2) 4583.1 ± 2902.5
LF power (msec2) 304.0 ± 275.9
HF power (msec2) 114.4 ± 235.0
SDNN (msec) 138.7 ± 36.5
SDANN (msec) 125.6 ± 35.0
rMSSD (msec) 26.2 ± 14.9
Genotypes [no. (%)]
GSTM1 deletion 594 (52.4)
GSTT1 deletion 199 (17.6)
GSTP1
Ile/Ile 550 (48.5)
Ile/Val 485 (42.8)
Val/Val 98 (8.7)
more detail elsewhere (Felber Dietrich et al.
2007). In brief, 52% of the subjects included
in the study were females. Mean age was 60.6
(SD 6.3) years, and mean BMI was 26.6 (4.2)
kg/m2. Non-log-transformed means (SDs) for
the different frequency-domain HRV para-
meters were TP, 4,583.1 msec2 (2,902.5);
HF, 114.4 msec2 (235.0); and LF, 304.0
msec2 (275.9). SHS exposure either at work
or at home was reported by 16% of the par-
ticipants. In the present subpopulation of
nonsmokers, 52% and 18% of subjects exhib-
ited homozygous GSTM1 and GSTT1 gene
deletion, respectively. Genotype distribution
for the GSTP1 Ile105Val SNP was 49%
(Ile/Ile), 43% (Ile/Val), and 8% (Val/Val).
Table 2 presents the independent associa-
tions of GST genotypes, SHS, and obesity
with changes in LF, HF, and TP HRV para-
meters. We observed no association for any of
the predictors with HF values. GSTT1 defi-
ciency, > 2 hr/day of SHS exposure, and obe-
sity were each independently associated with
lower TP and LF, and there was a trend
toward an association of GSTP1 (Ile105Val)
with TP. TP and LF were each 10% lower
among subjects homozygous for GSTT1 gene
deletion compared with participants without
the deletion (p = 0.02 and 0.04). The associa-
tions between HRV and GSTP1 were consis-
tent with the GSTT1 findings but did not
reach statistical significance. GSTM1 defi-
ciency was not associated with changes in any
HRV parameter. SHS (–17.6%, p = 0.006)
and obesity (–15.0%, p = 0.0003) were asso-
ciated with larger reductions in overall HRV
(TP) than were the genotypes. The associa-
tions of GST genotypes, obesity, and SHS
with HRV time-domain parameters were
generally consistent in direction with those
observed for frequency-domain parameters,
but reached statistical significance only for the
obesity association with both SDNN and
SDANN [see Supplemental Material, Table 1
(http://www.ehponline.org/members/2008/
11402/suppl.pdf)].
Table 3 and Figure 1 present the two-way
interactive effects of GST genotypes, SHS, and
obesity on HRV frequency-domain parame-
ters. To maximize power to detect an inter-
action, for these analyses we characterized SHS
exposure as either high (≥ 2 hr/day) or not. We
found significant two-way interactions for the
effect of high SHS exposure and GSTM1,
GSTT1, GSTP1, and obesity on TP. For
example, subjects with the GSTM1 deletion
and high SHS exposure had a 26.3% reduction
in TP (95% CI, –38.7% to –11.6%) (Figure
1), and obese subjects with high SHS exposure
had a 24.1% reduction in TP (95% CI,
–41.5% to –1.5%) compared with GSTM1
carriers and no or low SHS or absence of obe-
sity, respectively (Figure 1). In addition, for
LF, two-way interactions were also significant
for GSTT1, GSTP1, and obesity. In contrast,
we saw no interactions for HF.
The interaction between GSTT1 and SHS
was subadditive rather than superadditive, as
shown in Table 3. Subjects with the gene and
SHS had a 21.3% reduction in LF, subjects
with the gene deletion but no/low SHS had a
12.1% reduction in TP, but subjects with
both the high SHS exposure and the deletion
only had a 6.7% reduction in TP.
Further, treating obesity as the exposure,
we saw a significant two-way interaction with
GSTT1 for LF. In this case, the direction of
the interaction was superadditive.
Although, generally, we observed no sta-
tistically significant interactions between GST
genotypes, obesity, or SHS exposure and
time-domain parameters, there was a sugges-
tion for an elevated decrease in SDNN and
SDANN among subjects exhibiting both
GSTM1 deletion genotype and high SHS
exposure or obesity [see Supplemental
Material, Table 2 (http://www.ehponline.
org/members/2008/11402/suppl.pdf)].
The results presented above were unal-
tered when we adjusted them for any of the
additional potential confounders listed under
“Statistical analysis” (data not shown).
Additional control for heart rate and systolic
or diastolic blood pressure also did not mate-
rially alter these results. Additional analysis of
HRV restricted to the sleep period according
to diary information showed results similar to
those achieved in the 24-hr analyses. On aver-
age, LF power was lower at night by 11.1%
(p = 0.03) in the GSTT1-deficient group
compared with the reference group.
Discussion
We found associations between common GST
gene variants that are involved in oxidant
defense and HRV in the general population.
Participants missing both copies of the GSTT1
gene had, on average, 10% lower overall and
LF-domain HRV. GSTM1 deficiency and the
GSTP1 Ile105Val SNP were not indepen-
dently associated with HRV changes, but we
identified interactions between all three GST
polymorphisms and exposure to SHS for
effects on HRV. Combined with the interac-
tion of SHS with obesity, a condition known
to increase systemic oxidative stress, this pro-
vides support for the hypothesis that SHS
affects HRV through oxidative stress pathways.
This in turn implies that oxidative stress is an
important modifier of the autonomic control
of the heart, a hypothesis that has received little
attention until recently.
The hypothesis of oxidative stress being a
relevant pathophysiologic mechanism under-
lying individual variation in the functioning
of the autonomous nervous system, and
therefore HRV, is supported by (a) genetic
polymorphisms related to oxidative defenses
(Forsberg et al. 2001; Hayes and Strange
2000; Park et al. 2006) affecting HRV;
(b) conditions likely to increase oxidative
stress, such as obesity (Keaney et al. 2003)
and SHS (Zhang et al. 2002), decreasing
HRV; and (c) prooxidative conditions such as
obesity and SHS interacting with genetic
polymorphisms related to oxidative defenses.
Epidemiologic support for an association
between oxidative stress and the autonomic
control of the heart is still limited, but recent
evidence is supportive of this hypothesis. Data
in men from the Normative Aging Study
recently provided strong evidence that oxida-
tive stress may be a key pathway for the
adverse effects of combustion particles on
HRV (Schwartz et al. 2005). The association
between fine PM and reduced HRV was
restricted to persons missing the GSTM1 gene
and persons likely to have greater than average
baseline systemic inflammation and oxidative
stress, such as the obese. Statins, a widely pre-
scribed class of lipid-lowering drugs with sub-
stantial antiinflammatory and antioxidant
activity, protected GSTM1-deficient subjects
against the effects of fine PM (Schwartz et al.
2005). One key difference in our study is that
we aimed to assess the effect of a chronic
exposure (SHS, obesity) on baseline HRV,
rather than an acute one. Although some of
the observed associations can still be attrib-
uted to acute effects due to collinearity
Probst-Hensch et al
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Table 2. Percent difference (95% CI)a in HRV parameters according to GST genotypes, SHS, and obesity:
the SAPALDIA cohort study.
Genotype/exposure LF power HF power TP
GSTM1
Deletion vs. no deletionb –1.7 (–9.3 to 6.4) –1.6 (–11.2 to 9.0) –2.6 (–9.1 to 4.4)
GSTT1
Deletion vs. no deletionb –10.7 (–19.6 to –0.7) –3.4 (–15.6 to 10.5) –10.4 (–18.2 to –1.9)
GSTP1 to Ile105Val
Ile/Ile,Val vs. Val/Val –7.9 (–20.1 to 6.2) –8.6 (–23.8 to 9.7) –10.6 (–20.9 to 1.1)
SHS exposure
≤ 2 hr/day vs. none –10.3 (–22.3 to 3.5) –13.0 (–27.5 to 4.6) –4.3 (–15.5 to 8.2)
> 2 hr/day vs. none –16.4 (–28.8 to –1.9) –2.6 (–20.6 to 19.6) –17.6 (–28.3 to –5.4)
Obesity
≥ 30 vs. < 30 kg/m2 –19.5 (–27.4 to –10.8) –5.0 (–16.7 to 8.4) –15.0 (–22.2 to –7.2)
aAdjusted for study area, sex, age and (age)2, fruit intake, diabetes, and beta-blocker intake and mutually adjusted for
each other. bHomozygous gene deletion.
between chronic and acute exposure, the asso-
ciation with chronic exposure suggests an
ongoing and not a transitory impact on
HRV, which may have more public health
relevance. On the other hand, the similarity
between SHS and ambient PM is sufficiently
high that the finding of interactions of
GSTM1 status and obesity with these expo-
sures in two separate cohorts argues against
this being a chance finding.
The association of chronic stimuli such as
obesity, insulin resistance, and diabetes with
reduced HRV (Furukawa et al. 2004) is also
compatible with an ROS impact on the auto-
nomic nervous system. In nondiabetic human
subjects, fat accumulation and obesity are
closely correlated with markers of systemic
oxidative stress (Keaney et al. 2003; Olusi
2002). Diabetic patients are known to have
elevated oxidative stress levels, and they also
exhibit increased susceptibility to the effect
of air pollution on HRV (Zanobetti and
Schwartz 2002). Chronic administration of the
antioxidant vitamin E in a double-blind ran-
domized controlled trial in patients with type 2
diabetes and cardiac autonomic neuropathy
improved the ratio of the cardiac sympathetic
to parasympathetic tone (Manzella et al. 2001).
Marine- and plant-derived omega-3 fatty acid
supplementation in elderly nursing home resi-
dents was associated with a significant increase
in HRV (Holguin et al. 2005). The omega-3
fatty acid effects are possibly attributable in
part to their antioxidative properties (Mori
et al. 2003).
The exact mechanisms by which ROS
and associated inflammatory mediators affect
the autonomous nervous system and its corre-
late HRV are still poorly understood and
likely complex. Oxidants and inflammatory
mediators can act directly in the brain, as evi-
denced by the involvement of oxidative stress
in various neurodegenerative diseases such as
Alzheimer’s and Parkinson’s disease (Chong
et al. 2005). Inflammatory markers, including
interleukin-6, are present in the brain, where
they can influence the autonomic balance
(Juttler et al. 2002). A central nervous system
effect of ROS is also compatible with results
from a recent investigation in spontaneously
hypertensive rats that are characterized by ele-
vated oxidative stress (Girouard et al. 2004).
GST polymorphisms and heart rate variability
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Table 3. Percent difference (95% CI)a in HRV parameters according to combination of GST genotypes with passive smoking and obesity: the SAPALDIA
cohort study.
Genotype Exposure No. LF power HF power TP
GSTM1
No deletion No/low SHS 504 Referent Referent Referent
No deletion High SHS 35 –11.5 (–30.0 to 27.7) –2.2 (–12.0 to 8.7) –4.6 (–22.0 to 16.7)
Deletionb No/low SHS 551 –1.2 (–9.0 to 7.3) –5.5 (–30.0 to 27.7) –0.8 (–7.7 to 6.4)
Deletionb High SHS 35 –19.9 (–35.4 to –0.7) 1.6 (–22.8 to 33.9) –26.3 (–38.7 to –11.4)
p-Value for trendc 0.094 0.86 0.014
No deletion Not obese 437 Referent Referent Referent
No deletion Obese 102 –13.3 (–25.3 to 0.7) 1.6 (–16.2 to 23.0) –3.0 (–14.7 to 10.4)
Deletionb Not obese 473 1.2 (–7.5 to 10.6) 1.0 (–16.2 to 23.0) 2.4 (–5.2 to 10.6)
Deletionb Obese 121 –23.5 (–33.4 to –12.0) –9.4 (–24.2 to 8.2) –22.1 (–30.9 to –12.1)
p-Value for trendc 0.16 0.69 0.25
GSTT1
No deletion No/low SHS 871 Referent Referent Referent
No deletion High SHS 63 –17.6 (–30.9 to –1.7) –3.0 (–22.6 to 21.5) –21.3 (–32.3 to –8.5)
Deletionb No/low SHS 184 –11.1 (–20.2 to –0.7) –4.1 (–16.7 to 10.3) –12.1 (–20.0 to –3.5)
Deletionb High SHS 15 –16.5 (–41.1 to 18.5) 6.9 (–31.8 to 67.4) –6.7 (–30.9 to 25.9)
p-Value for trendc 0.007 0.77 0.002
No deletion Not obese 748 Referent Referent Referent
No deletion Obese 186 –18.1 (–26.7 to –8.4) –5.3 (–18.0 to 9.3) –15.1 (–22.9 to –6.4)
Deletionb Not obese 162 –8.7 (–18.8 to 2.6) –3.5 (–16.9 to 12.1) –10.3 (–19.0 to –0.8)
Deletionb Obese 37 –33.1 (–46.7 to –16.0) –7.3 (–30.8 to 24.0) –24.5 (–37.9 to –8.1)
p-Value for trendc 0.011 0.79 0.084
GSTP1, Ile105Val
Val/Val No/low SHS 87 Referent Referent Referent
Val/Val High SHS 11 –16.9 (–45.9 to 27.7) 13.4 (–34.6 to 99.5) –9.4 (–37.3 to 32.0)
Ile/Ile,Val No/low SHS 969 –7.9 (–20.7 to 7.0) –6.5 (–22.9 to 13.3) –9.7 (–20.6 to 2.7)
Ile/Ile,Val High SHS 67 –22.6 (–37.8 to –3.6) –9.4 (–31.6 to 19.9) –26.4 (–39.1 to –11.2)
p-Value for trendc 0.020 0.53 0.011
No deletion Not obese 79 Referent Referent Referent
No deletion Obese 19 –2.2 (–30.7 to 38.0) 6.6 (–31.4 to 65.6) 10.5 (–17.9 to 48.8)
Deletionb Not obese 831 –4.1 (–18.1 to 12.4) –6.3 (–23.5 to 14.7) –5.5 (–17.5 to 8.4)
Deletionb Obese 204 –24.1 (–36.5 to –9.2) –11.9 (–29.9 to 10.8) –21.8 (–32.8 to –8.5)
p-Value for trendc 0.073 0.66 0.33
Obesity
No/low SHS Not obese 855 Referent Referent Referent
No/low SHS Obese 200 –1.2 (–18.0 to 19.1) 9.9 (–13.5 to 29.1) –12.1 (–25.2 to 3.2)
High SHS Not obese 55 –3.4 (–17.4 to 13.0) 5.6 (–13.7 to 29.1) 5.4 (–7.9 to 20.7)
High SHS Obese 23 –44.4 (–58.9 to –24.8) –18.6 (–44.9 to 20.0) –24.1 (–41.5 to –1.5)
p-Value for trendc 0.002 0.76 0.049
aAdjusted for study area, sex, age and (age)2, fruit intake, diabetes, and beta-blocker intake and mutually adjusted for each other. We did not mutually adjust GST polymorphisms for
each other. We adjusted GST/SHS models for BMI as a continuous variable, and adjusted GST/obesity models for SHS. bHomozygous deletion. cWe derived the p-values for trend by
entering a cross-categorized variable coded as 1, 2, and 4 for subjects exhibiting 0, 1, or 2 at-risk characteristics, respectively.
Figure 1. Combined effects (percent change and
95% CI) of GSTM1 genotype [deletion (del) vs. no
deletion], obesity (obese vs. not obese), and SHS
(high SHS vs. no/low SHS) exposure on TP.
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The antioxidants N-acetylcysteine and mela-
tonin restored cardiac baroreflex to normal,
but not blood pressure, an effect that could be
attributable to a central nervous system ROS
effect. Interestingly, these rats were character-
ized by a primarily sympathetic defect, and our
study finds the effects of SHS, obesity, and
GST polymorphisms are absent for HF, which
reflects a primarily parasympathetic response.
Finally, ROS and inflammatory markers
may further exacerbate the autonomic
disturbances on the heart through peripheral
local effects on heart structures (Lee and
Widdicombe 2001), because oxidative stress is
the most commonly hypothesized mechanism
by which several cytotoxic anticancer drugs
cause cardiotoxicity (Stone and Godleski 1999).
Tracey (2002) describes the central role of the
autonomous nervous system in monitoring as
well as regulating oxidative stress and inflam-
mation at innervated pulmonary and extrapul-
monary sites as the inflammatory reflex. In
accordance with the inflammatory reflex model
and our results, recent studies in rats intratra-
cheally exposed to urban PM suggested a pul-
monary-to-cardiac signaling model with
pulmonary oxidants increasing cardiac oxidant
concentrations under the strict control of the
autonomous nervous system. Cardiac oxidative
stress was preventable by both N-acetylcysteine
and β1 receptor antagonist pretreatment of
these animals (Rhoden et al. 2005).
The respective impact of the different GST
polymorphisms on HRV observed in this
study further elucidates ROS mechanisms. The
GST genes and isozymes exhibit differences in
tissue expression as well as substrate specificity
(Forsberg et al. 2001; Hayes and Strange
2000). Although liver is the only rich source of
the GSTM1 isozyme, where it is the predomi-
nant form, GSTP1 and GSTT1 are expressed
in various tissues, including heart, brain, lung,
and liver (Hayes and Strange 2000; Rowe et al.
1997). The presence of GSTT1 and—statisti-
cally nonsignificant—GSTP1 main effects and
the absence of a GSTM1 main effect on HRV
are consistent with an impact of locally and
endogenously produced ROS in lung, heart,
brain, and possibly additional organs on the
activity of the autonomous nervous system.
The hypothesis that endogenously produced
oxidative stress affects the nervous system is
further supported by the observation that lack
of GSTT1, but not of other GST variants, is
generally associated with increased susceptibil-
ity to brain diseases, including brain tumors
and neurodegenerative diseases, even in appar-
ently unexposed individuals (Landi 2000).
The modifying effect of GSTM1 for the
association of SHS with HRV suggests that
these exposures cause systemic oxidative stress
that is being scavenged by GSTM1 in the
liver. The modification of the SHS effect by
GSTM1 is consistent with previous studies on
the association between SHS, GST polymor-
phisms, and lung cancer in never smokers
(Wenzlaff et al. 2005) and may reflect the
additional impact of GSTM1 on liver metabo-
lism of tobacco-derived electrophils (Hayes
and Strange 2000; Landi 2000; Rowe et al.
1997). The modifying effect of GSTP1 vari-
ants suggests that oxidative stress in target tis-
sues other than liver is also important for the
effects of SHS. The observation of subadditive
effects of GSTT1 and SHS, in contrast to the
superadditive effects of GSTT1 and obesity,
suggest that some specific components of
SHS drive the direction of the interaction.
Depending on the substrate, GSTT1-catalyzed
reactions can actually increase toxicity (Landi
2000). What that component is remains to
be determined.
This study has a number of limitations. In
all genetic studies, the prevalence of the poly-
morphism can limit power. A greater concern
in this study is the 6.9% prevalence rate for
high SHS exposure, which clearly limits
power in gene-by-environment interactions.
An additional limitation of this study is its
cross-sectional design. We recorded electro-
cardiograms once for each subject. The future
longitudinal assessment at the next follow-up
examination will allow for improved adjust-
ment of within-subject variation and allow us
to examine differences in baseline autonomic
function over time. The aging of the cohort
will provide information on the combined
impact of modifiable and genetic factors on
the course of HRV decline and on the inci-
dence of cardiac diseases. Finally, although
the reported associations were comparable for
frequency- and time-domain parameters, they
were generally stronger and more consistent
in the frequency domain. 
However, the focus on frequency-domain
parameters seems justified. First, the frequency-
domain parameter HF captures the vagal,
parasympathetic response more clearly than
does rMSSD. Second, the Fourier transforma-
tion for TP, but not SDNN, is for a specified
frequency range that trims off some ultra-HF
signals. Extending the upper limit of the HF
component, which is implicitly lacking in
SDNN, beyond 0.4 Hz would be applicable
only to extreme tachypnea of > 24 respiratory
cycles per minute. This is linked to extreme
sympathetic overdrive, under which it is rather
difficult to interpret the HF component.
Moreover, because the cardiac period signal is
discrete rather than continuous, it is difficult to
properly estimate respiratory arrhythmia under
such conditions of very fast tachypnea.
In conclusion, our results are consistent
with an important role of oxidative stress in
the autonomic control of the heart and, possi-
bly, in individual variability in autonomous
nervous system activity. If confirmed by addi-
tional studies specifically investigating the
association between systemic oxidative stress
markers and HRV, these findings have sub-
stantial public health relevance. Tsuji et al.
(1996) suggested that a 1-SD reduction in
overall HRV was associated with a relative
risk of 1.47 for cardiac events over 3.5 years
of follow-up. Although differences in study
design preclude a quantitative risk estimate,
the observed reduction in overall HRV in
subjects with SHS exposure (>2 hr) and either
obesity, GSTM1 deletion, or GSTP1 substitu-
tion in our study suggests a nontrivial eleva-
tion of cardiovascular risk on follow-up, and
one similar to what has in fact been reported
for SHS exposure (Law and Wald 2003).
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